Multinational corporations constantly face an increasingly competitive global environment. 

As commercial prospects diminish in developed markets – due to declining economic growth, regulatory challenges, pricing pressures and patent expirations – corporations are continuously reassessing their international strategies.  One alternative path has been to selectively expand into what are referred to as "emerging markets." 

These markets are not uniform, and each country needs to be reviewed on its own merits. 

Corporate stakeholders with specific areas of expertise need to be consulted prior to market entry and during the early and crucial stages of operations to ensure strategies are being executed in a pragmatic manner. 

Meet the Expert

Derek Kosti

Consultant Derek Kosti
Emerging Markets Strategist, Independent Consultant
Fairfield , CT

Skills and Expertise: What's this?

About Derek

  • International finance professional with more than 20 years of experience in the pharmaceutical industry with a Fortune 100 Company
  • Former finance lead for Asia, China, Indonesia, Eastern Europe and a newly established European business unit focusing on revenue growth, profitability improvement, expense rationalization, distribution strategies and restructuring 
  • Designed finance structures including a new international controller role with oversight for more than 100 markets and hubs specializing in US GAAP, compliance, restructuring, sales recognition, joint-ventures and business collaborations
  • Formulated and executed international commercial strategies in conjunction with multiple stakeholders
  • Currently an independent consultant working with clients on identifying commercial opportunities in international markets
  • Fluent in Mandarin Chinese

Experience

Independent Consultant •
Aug, 2017 — Present
  • As an independent consultant, assists companies in identifying commercial opportunities and executing strategies in international markets.
  • Provides support in areas such as contract negotiations, distribution models, operational due diligence, organizational design alternatives and risk mitigation.
Biopharmaceutical Businesses Controller - International • Pfizer
2008 — 2017
  • Designed the first international divisional controllers structure for Pfizer's biopharmaceutical businesses and led a team in Europe, Latin America, Africa/Middle East and Asia to ensure the integrity of US GAAP reporting for more than 100 regional hubs and markets, with cumulative annual revenues of about $20 billion. 
  • Identified strategies to mitigate financial and operational exposure to Pfizer by incorporating multiple factors in risk models. 
  • Imparted guidance to markets on accounting issues relating to collaboration arrangements, revenue recognition, sales deductions, legal provisions, joint-ventures and restructuring.
  • Collaborated with consulting firms and internal teams to assess the financial impact of the future implementation of the new 'Revenue Recognition' and 'Leasing' accounting standards on Pfizer's global operations.                                                                                                                                                                     
Senior Finance Director • Pfizer 
2000 — 2008
  • As Senior Finance Director, led teams in Central-Southern Europe, Asia, and Northern Europe to achieve Enterprise financial and strategic objectives.
  • Designed financial reporting processes and identified commercial opportunities for a newly established business unit focused on products that had lost exclusivity.
  • Guided the Pfizer Russia Board of Directors. 
  • Executed operational and legal integrations in multiple international markets relating to the Warner-Lambert and Pharmacia acquisitions.
  • Co-led China strategy that assessed distribution networks, legal structures and commercial strategies.   
Finance Director and Interim Country Manager - Indonesia • Pfizer
1998 — 2000
  • Led the publicly-listed Pfizer Indonesia legal entity with annual revenues of about $20 million.  Headed multifunctional task force to establish a marketing joint venture with a major Indonesian pharmaceutical company.
Controller/Budget & Audit Director - China   • Pfizer
1996 — 1998

  • Formulated a risk management system and enhanced internal controls by establishing policies & procedures for Pfizer’s joint-venture.  

Education

Thunderbird School of Global Management
MBA, International Finance, 1984

Academic Awards

Academic Scholarship
University of Wisconsin-River Falls
Bachelor of Arts, Business Administration, French, 1982

Academic Honors

Senior Honors
Harvard Leadership Development Program, 2002

Licenses & Certifications

Chartered Professional Accountant
Chartered Accountant - Canadian Institute of Chartered Accountants

Panels

  • 2017 Malaysia Midwest Games - Assessing the value of an overseas education
  • CBI Conference (Philadelphia) - Implementing the new Revenue Recognition Standard
  • Harvard Club; CFO Conference - Challenges faced by a CFO
Packages with Derek starting from $900

Your Expert Package Includes:

Best Practices

Access to ALL Best Practices authored by TrustedPeer Expert Derek Kosti on this topic.

Pre-Meeting Discovery Process

Review and analysis of your issue with pre-meeting discovery questions by Derek, followed by a 30- or 60-minute one-on-one call. Sample

One+-on-One Call

Your (+colleagues) meeting is directed and focused from the first minute.

Meeting Summary Report

After your call, Derek completes a Meeting Summary Report to provide you with the session’s discussion topics, analysis, assessment and recommendations for next steps. Sample

Post-Meeting Engagement

After your meeting, continue your relationship with Derek on your own, or with TrustedPeer’s support.
Loading...